The ALS Society of Canada (ALS Canada) and Brain Canada have awarded a combined $515,000 to support four early-career clinicians and researchers advancing care and scientific understanding of amyotrophic lateral sclerosis (ALS). ALS Canada and Brain Canada have been partners since 2014, with early support stemming from…
News
The U.S.-based advocacy group I AM ALS has secured $313 million in new federal funding for Push for Progress, an effort the nonprofit launched in late 2025 to accelerate research and expand access to treatments for amyotrophic lateral sclerosis (ALS). In a press release announcing the…
No U.S. state earned the highest possible score on the ALS Association‘s annual ALS State Policy Report Cards for policies supporting people with amyotrophic lateral sclerosis (ALS) this year, and several averaged failing grades. The report cards are designed to provide a…
Glycogen, an inflammatory sugar molecule produced by certain gut bacteria, may play a key role in driving amyotrophic lateral sclerosis (ALS), a study found. Treatments to degrade glycogen reduced inflammation and extended survival in an animal model of the disease, and clinical trials to test this approach in people…
ALS ONE, a Massachusetts-based nonprofit focused on accelerating research into amyotrophic lateral sclerosis (ALS), will soon become part of the ALS Network, an ALS advocacy organization that serves people with ALS in California and Hawaii. “This moment marks a real inflection point for the ALS community,” Sheri…
Elite athletes, military veterans, first responders, and other high performers have a significantly higher risk of developing amyotrophic lateral sclerosis (ALS) than the general population, and a new study aims to find out why. The initiative, Champion Insights, is seeking up to…
The first patient has been dosed in a Phase 1/2 clinical study of VTx-002, an experimental therapy being developed by VectorY Therapeutics for amyotrophic lateral sclerosis (ALS). The open-label PIONEER-ALS (NCT07287397) is enrolling up to 12 adults with ALS at sites in the U.S. and Europe. They will…
Origami Therapeutics is collaborating with Ipsen to develop experimental therapies designed to remove or correct abnormal proteins that build up in neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). The partnership will focus on small molecules known as protein degraders and correctors. These compounds are designed to…
Coya Therapeutics has raised about $11.1 million in a private investment round to support commercial-readiness efforts for COYA 302, its experimental immune-modulating therapy being developed for amyotrophic lateral sclerosis (ALS). The funding was secured through the sale of more than 2.5 million company shares to two investors, the company…
A bipartisan team of U.S. lawmakers has reintroduced the ALS Better Care Act, a bill that aims to improve access to quality medical care for people with amyotrophic lateral sclerosis (ALS). The legislation was introduced in the House by Republican Brian Fitzpatrick of Pennsylvania and Democrats Jason Crow…
Recent Posts
- Grants support next generation of ALS researchers in Canada
- ALS research wins big bucks with $313M in new US government funding
- Guest Voice: I’m leaving behind a legacy of love through letters
- ALS report cards show how US states fall short on patient support
- Feeding wildlife reminded me what’s important in life after ALS